BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
PRKCA
,
T cell receptor signaling pathway
,
Obesity
,
Prostate
,
Alcohol
,
Bleomycin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
pegvisomant
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
GHR
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
Growth hormone-binding protein
Long hematopoietin receptor, single chain, conserved site
Growth hormone/erythropoietin receptor, ligand binding
GERHOLD_RESPONSE_TO_TZD_DN
REACTOME_PROLACTIN_RECEPTOR_SIGNALING
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Drug target sets for approved compounds
Explore Curated Studies Results
Literature
Most Relevant Literature
Pegvisomant and cabergoline combination therapy in acromegaly.
Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resista…
Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a sev…
Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects i…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Pasireotide LAR and Pegvisomant Study in Acromegaly
Acute Application of Pegvisomant and Octreotide in Acromegaly
Tissue Biomarker for Pegvisomant Action
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ